A US-based KOL addresses the current treatment paradigms in AML, with a focus on lines of therapy in the relapsed/refractory setting. Pipeline drugs across all settings are also discussed, as well as treatment failures as a major area of unmet need in AML. 

This interview was conducted on 23 July 2024. 

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.